LONG-TERM EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 2 YEARS
William J. Sandborn(University of San Diego), Bruno Silva, C Gasink, Stephan R. Targan(Cedars-Sinai Medical Center), Jürgen M. Stein(Unknown), L-L Gao(Janssen (United States)), Subrata Ghosh(University College Cork), P. Rutgeerts, J F Colombel(Icahn School of Medicine at Mount Sinai), W de Villiers(University of Cape Town), B. Feagan, Stephen B. Hanauer(Northwestern University), Jewel Johanns(Johnson & Johnson (United States)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 6
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k